Baseret på data opnået i disse studier og fordi ritonavir ikke forventes at have nogen signifikant indvirkning på farmakokinetikken for NRTI’ erne, forventes den samtidige administration af fosamprenavir og ritonavir med disse lægemidler ikke at ændre virkningen af disse.
Based on data derived from these studies and because ritonavir is not expected to 7 have a significant impact on the pharmacokinetics of NRTIs, the co-administration of fosamprenavir and ritonavir with these medicinal products is not expected to significantly alter the exposure of the co-administered active substances.